FIG 1.
(A) RFS and (B) OS in 39 response-evaluable patients who were treated with neoadjuvant GC with atezolizumab. GC, gemcitabine and cisplatin; OS, overall survival; RFS, relapse-free survival.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.